STAT - Reporting from the frontiers of health and medicine

Health

First Opinion

By Elizabeth Baker

Pharmalot

Pharmalot Endo agrees to pay $10 million to settle landmark opioid case brought by Ohio counties
Biotech Top scientist categorically denies any wrongdoing in Novartis data manipulation scandal
Biotech Sarepta stumbles on FDA rejection of a new drug to treat Duchenne muscular dystrophy
Pharmalot AIDS activists say Gilead put profits over patients — and misled Congress about an HIV pill
Politics Despite their pledges, Democrats haven’t yet lowered drug prices. Here’s how they’re explaining themselves

Exclusive analysis of biotech, pharma, and the life sciences

Daily, market-moving coverage of biotech and pharma

Inside intelligence on the NIH, the FDA, and Congress

Profiles of the power players shaping the industry

Analysis of the latest scientific developments

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future
Drug maker pays $200,000 to settle charges of unfairly disclosing material info to analysts
Pharmalittle: Two drug makers may settle opioid case; FDA hands Sarepta a surprising setback

Special Report

First Opinion

By Dorothy Pomerantz

Exclusive

Special Report

Health Tech

Biotech

Biotech A writer shared her story about getting frightening genetic results online. The response was surprising
Adam's Take FDA’s Sarepta rejection is rooted in the past, and will weigh on its future
Pharmalot AIDS activists say Gilead put profits over patients — and misled Congress about an HIV pill
Health Why fentanyl is deadlier than heroin, in a single photo
Biotech Sarepta stumbles on FDA rejection of a new drug to treat Duchenne muscular dystrophy